Allurion Technologies WarrantsALUR.WS
About: Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 137
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.54% less ownership
Funds ownership: 6.35% [Q4 2024] → 5.81% (-0.54%) [Q1 2025]
13% less funds holding
Funds holding: 38 [Q4 2024] → 33 (-5) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
58% less capital invested
Capital invested by funds: $601K [Q4 2024] → $253K (-$349K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ALUR.WS.
Financial journalist opinion
We haven’t received any recent news articles for ALUR.WS.